"Survival Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
| Descriptor ID |
D015996
|
| MeSH Number(s) |
E05.318.308.985.550.900 N01.224.935.698.826 N06.850.505.400.975.550.900 N06.850.520.308.985.550.900
|
| Concept/Terms |
Survival Rate- Survival Rate
- Rate, Survival
- Rates, Survival
- Survival Rates
Mean Survival Time- Mean Survival Time
- Mean Survival Times
- Survival Time, Mean
- Survival Times, Mean
- Time, Mean Survival
- Times, Mean Survival
Cumulative Survival Rate- Cumulative Survival Rate
- Cumulative Survival Rates
- Rate, Cumulative Survival
- Rates, Cumulative Survival
- Survival Rate, Cumulative
- Survival Rates, Cumulative
|
Below are MeSH descriptors whose meaning is more general than "Survival Rate".
Below are MeSH descriptors whose meaning is more specific than "Survival Rate".
This graph shows the total number of publications written about "Survival Rate" by people in this website by year, and whether "Survival Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 7 | 7 |
| 1996 | 0 | 6 | 6 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 6 | 6 |
| 2003 | 1 | 6 | 7 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 13 | 13 |
| 2010 | 1 | 5 | 6 |
| 2011 | 0 | 9 | 9 |
| 2012 | 1 | 14 | 15 |
| 2013 | 0 | 9 | 9 |
| 2014 | 0 | 11 | 11 |
| 2015 | 0 | 16 | 16 |
| 2016 | 0 | 12 | 12 |
| 2017 | 0 | 18 | 18 |
| 2018 | 0 | 13 | 13 |
| 2019 | 1 | 15 | 16 |
| 2020 | 0 | 10 | 10 |
| 2021 | 0 | 15 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Survival Rate" by people in Profiles.
-
LTA4H Prevalence and Mortality in Adult Zambians with Tuberculous Meningitis. Ann Neurol. 2021 12; 90(6):994-998.
-
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res. 2021 10; 109:106629.
-
Redefining the Risk of Surgery for Clinical Stage IIIA (N2) Non-Small Cell Lung Cancer: A Pooled Analysis of the STS GTSD and ESTS Registry. Lung. 2021 06; 199(3):311-318.
-
Laryngeal Chondrosarcoma Characteristics and Survival Analysis in the National Cancer Database. Otolaryngol Head Neck Surg. 2022 01; 166(1):101-108.
-
Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma. Oncology. 2021; 99(5):310-317.
-
Just the facts: updates in COVID-19 therapeutics. CJEM. 2021 May; 23(3):283-285.
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
-
Evolving from Morbidity and Mortality to a Case-based Error Reduction Conference: Evidence-based Best Practices from the Council of Emergency Medicine Residency Directors. West J Emerg Med. 2020 Oct 06; 21(6):231-241.
-
Melflufen for relapsed and refractory multiple myeloma. Expert Opin Investig Drugs. 2020 Oct; 29(10):1069-1078.
-
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660-e670.